Last updated: August 18, 2026
Kedrion Biopharma is a privately held, Italy-based plasma-derived therapeutics company with a growing U.S. presence and expanded manufacturing scale following its acquisition of Bio Products Laboratory. Its competitive position rests on plasma collection, fractionation capacity, regulatory approvals, hospital distribution and specialized immunoglobulin products rather than on a large portfolio of conventional small-molecule patents.
Kedrion’s principal competitors are CSL Behring, Grifols, Takeda, Octapharma, Biotest and ADMA Biologics. The company has meaningful positions in intravenous immune globulin, rabies immune globulin, hepatitis B immune globulin and other plasma-derived products. Its main strategic risks are plasma supply, manufacturing utilization, pricing pressure, quality compliance, customer concentration and competition from larger fractionators with broader collection networks.
What is Kedrion Biopharma’s market position in plasma-derived medicines?
Kedrion is a mid-sized global plasma-products manufacturer with a stronger position in specialized immunoglobulin products than in broad commercial scale.
The company operates across the plasma-derived value chain:
- Plasma collection and donor sourcing
- Plasma testing and viral inactivation
- Fractionation and purification
- Fill-finish manufacturing
- Hospital and specialty-pharmacy distribution
- Development and commercialization of immunoglobulin and hyperimmune products
Kedrion’s U.S. subsidiary, Kedrion Biopharma Inc., markets products in a regulatory environment dominated by CSL Behring, Grifols, Takeda and Octapharma. The acquisition and integration of BPL expanded Kedrion’s manufacturing and product footprint, particularly in immunoglobulins and albumin.
Principal commercial products
| Product |
Active substance or category |
Primary use |
Competitive relevance |
| BIVIGAM |
Intravenous immune globulin, human |
Primary humoral immunodeficiency |
U.S. IVIG product with hospital and specialty distribution |
| GAMMAKED |
Immune globulin injection, human |
Primary immunodeficiency |
Competes in a concentrated IVIG and subcutaneous-adjacent market |
| GAMMAPLEX |
Intravenous immune globulin, human |
Primary immunodeficiency and other immune disorders |
Product differentiation depends on formulation, manufacturing and supply reliability |
| KEDRAB |
Human rabies immune globulin |
Post-exposure prophylaxis for rabies |
Specialized hyperimmune product with public-health and hospital demand |
| GamaSTAN |
Immune globulin, human |
Passive immunization |
Established hyperimmune and infectious-disease product category |
| Albumin and other plasma products |
Human albumin and fractionated plasma proteins |
Critical care and replacement therapy |
Supports portfolio breadth and fractionation economics |
Product availability, labeling and commercial ownership can vary by jurisdiction. The FDA-approved labeling for BIVIGAM, GAMMAKED, GAMMAPLEX and KEDRAB remains the primary source for U.S. indications and administration requirements. [1-4]
How does Kedrion compare with CSL Behring, Grifols, Takeda and Octapharma?
Kedrion is smaller than the largest integrated plasma companies but competes through product specialization, geographic reach and manufacturing relationships.
| Company |
Core competitive advantage |
Relative position versus Kedrion |
| CSL Behring |
Large plasma-collection network, global scale, immunoglobulin and specialty biologics |
Greater scale, broader portfolio and stronger supply resilience |
| Grifols |
Extensive plasma centers, fractionation infrastructure and global commercial footprint |
Larger collection base but exposed to leverage, execution and supply-chain pressures |
| Takeda |
Global specialty-pharma infrastructure and broad immunoglobulin portfolio |
Stronger commercial organization and diversified biologics portfolio |
| Octapharma |
Integrated plasma operations and global immunoglobulin manufacturing |
Comparable focus in plasma products with substantial European and international presence |
| Biotest |
Plasma-derived medicines and specialized products |
Product and manufacturing overlap; strategic relationship history with Kedrion |
| ADMA Biologics |
U.S.-focused plasma-derived immunoglobulin products |
Smaller scale, more concentrated portfolio and U.S.-centric strategy |
| Kedrion |
Mid-sized plasma fractionator with specialized immune and hyperimmune products |
More focused portfolio and smaller collection scale than the largest competitors |
Kedrion’s strongest relative position is in products where regulatory approval, manufacturing qualification and hospital procurement create barriers to rapid entry. Its weaker position is in products where customers can substitute among several FDA-approved IVIG suppliers and where large competitors can use scale to manage plasma and manufacturing costs.
What patents protect Kedrion’s plasma-derived products?
Kedrion’s commercial protection is primarily regulatory and manufacturing-based rather than dependent on a dense composition-of-matter patent estate.
Plasma-derived products generally contain naturally occurring human proteins. Their core active substances, including polyclonal immunoglobulin and albumin, are difficult to protect with conventional pharmaceutical composition patents. Protection instead may arise from:
- Manufacturing and purification processes
- Viral-clearance and pathogen-reduction methods
- Stabilization and excipient systems
- Concentration and formulation methods
- Container-closure configurations
- Device or administration systems
- Trade secrets covering fractionation, yield and quality control
- FDA biologics licensing and manufacturing approvals
- Product-specific clinical and regulatory data
Patent rights are product-specific. A company-level patent count would not provide a reliable measure of Kedrion’s commercial defensibility because many relevant process patents may be owned by affiliates, licensors, contract manufacturers or predecessor companies.
What formulations are protected by Kedrion-related patents?
Potentially protectable formulation features include protein concentration, pH, stabilizers, excipients, low-temperature processing, aggregation control and shelf-life improvements. For IVIG products, the practical commercial value of such patents depends on whether a competing manufacturer can design around the formulation while meeting FDA comparability, safety and quality requirements.
Formulation patents are usually narrower than composition-of-matter patents. They may still delay competition when they cover a commercially important product presentation or a manufacturing step that improves yield, stability or tolerability.
Does Kedrion have Orange Book-listed patents?
The Orange Book is not the principal patent database for Kedrion’s biologic products.
FDA-regulated plasma-derived products are generally licensed as biologics under the Public Health Service Act. The FDA’s Purple Book, biologics license records and product labeling are more relevant than the Orange Book for assessing reference-product status, biosimilar pathways and exclusivity. [5]
A product may have related patents listed in FDA patent systems if it is regulated as a drug rather than a biologic, or if a specific listing mechanism applies. The presence or absence of an Orange Book listing should not be treated as a complete measure of Kedrion’s intellectual-property position.
When do Kedrion products lose exclusivity?
There is no single Kedrion exclusivity date because each product has a separate approval history, regulatory classification and patent profile.
Regulatory exclusivity
For biologics approved under Section 351(a), the reference product generally receives 12 years of reference-product exclusivity from first licensure under the Biologics Price Competition and Innovation Act. Orphan-drug exclusivity may provide seven years for a qualifying indication, while pediatric exclusivity can add six months to applicable exclusivity periods. [6-7]
Many plasma-derived products have long histories and may not retain meaningful standalone regulatory exclusivity. A competing product may still face practical barriers because it must establish manufacturing consistency, demonstrate safety and effectiveness, secure adequate plasma supply and pass FDA inspection.
Patent expiry
Patent expiration depends on the specific patent family. Process and formulation patents commonly expire independently of the underlying biologic license. Patent-term adjustment, patent-term extension, terminal disclaimers and foreign prosecution can affect the effective end date.
For Kedrion, the relevant diligence unit is the individual product and its U.S. patent and regulatory record, not the company’s overall portfolio.
Are Kedrion products vulnerable to Paragraph IV challenges?
Paragraph IV litigation is generally associated with the Hatch-Waxman pathway for small-molecule drugs and Orange Book-listed patents. It is not the standard pathway for most plasma-derived biologics.
For Kedrion’s biologic products, competitive entry is more likely to involve:
- A full biologics license application under Section 351(a)
- A biosimilar application under Section 351(k), where legally and scientifically applicable
- A competing plasma-derived product supported by its own manufacturing and clinical data
- Administrative patent challenges involving process or formulation patents
- Trade-secret, contract, regulatory or product-liability disputes
A generic applicant cannot normally rely on a conventional ANDA pathway to enter the market for a complex plasma-derived biologic. This reduces the probability of an immediate automatic substitution event but does not eliminate competition.
What is the biosimilar risk for Kedrion?
Biosimilar risk is moderate at the category level but uneven across products.
Polyclonal plasma-derived immunoglobulins are more difficult to copy than structurally defined monoclonal antibodies because they contain heterogeneous antibody populations that depend on donor pools, collection geography and fractionation processes. A competitor must demonstrate a highly controlled manufacturing process and establish clinical and analytical comparability appropriate to the product.
The principal risks are therefore:
- New plasma-derived competitors obtaining separate FDA licenses.
- Larger manufacturers increasing IVIG production.
- Hospital buyers shifting volume during supply shortages or contract renewals.
- Intravenous products competing with subcutaneous immunoglobulin.
- Pricing pressure from public and institutional purchasers.
Biosimilar substitution rules also differ from conventional generic substitution. An FDA biosimilar designation does not automatically make a product interchangeable. Interchangeability requires a separate regulatory determination. [5]
What litigation affects Kedrion Biopharma?
Kedrion’s material litigation exposure is more likely to arise from product liability, manufacturing compliance, commercial contracts, employment matters and patent disputes involving specific products than from a single, high-profile Orange Book patent case.
The most strategically important legal risks are:
- FDA warning letters, manufacturing observations or license restrictions
- Product recalls or supply interruptions
- Patent disputes involving formulation or manufacturing processes
- Contract disputes with distributors and plasma suppliers
- Competition-related disputes following acquisitions
- Product-liability claims involving immune globulin or hyperimmune products
The acquisition of BPL also creates integration and diligence considerations involving manufacturing sites, product registrations, quality systems, employees, supply contracts and inherited liabilities. Publicly available information does not establish a single company-wide patent litigation event that determines Kedrion’s market access.
What licensing deals and strategic transactions shape Kedrion?
The most important strategic transaction affecting Kedrion’s competitive position is its acquisition of BPL with financial backing from Permira-related investment vehicles. The transaction expanded Kedrion’s plasma-derived product portfolio, manufacturing footprint and international reach. [8]
This was an acquisition rather than a conventional product license. It increased the combined company’s ability to:
- Source and process plasma
- Supply immunoglobulin and albumin
- Maintain multiple manufacturing locations
- Serve government and hospital customers
- Spread fixed manufacturing costs across a broader portfolio
- Compete for plasma and institutional contracts
Kedrion’s commercial model also relies on distribution and supply relationships that may not be publicly disclosed in full. Those arrangements can materially affect regional market access without creating a visible patent right.
How strong is Kedrion’s patent estate?
Kedrion’s patent estate is best characterized as moderate in defensive value and secondary to its manufacturing platform.
| Protection category |
Estimated strategic value |
Assessment |
| Composition-of-matter patents |
Low to moderate |
Limited for naturally occurring plasma proteins |
| Formulation patents |
Moderate |
Can protect stability, concentration and tolerability features |
| Manufacturing patents |
Moderate to high |
Relevant to yield, purity, viral clearance and scale |
| Trade secrets |
High |
Process parameters and plasma fractionation know-how are difficult to replicate |
| Regulatory approvals |
High |
Manufacturing qualification and clinical history create entry friction |
| Plasma supply network |
High |
Scarce donor supply is a core barrier to rapid expansion |
| Brand and procurement relationships |
Moderate |
Important in hospitals and public-health channels |
| Device patents |
Product-specific |
Value depends on delivery presentation and design-around options |
The strongest barrier is not a single blocking patent. It is the combination of plasma access, manufacturing validation, regulatory history, product reliability and commercial distribution.
What generic launch scenarios exist for Kedrion products?
Kedrion faces three principal entry scenarios.
Scenario 1: Gradual competitive entry
A new plasma-derived manufacturer enters with a separate biologics license. This is the most plausible route for mature IVIG and hyperimmune categories. Entry would likely begin with limited contracted volume rather than immediate national substitution.
Scenario 2: Capacity-driven price pressure
A major competitor adds fractionation capacity or reallocates plasma toward IVIG. Kedrion could face lower pricing even without a direct patent challenge. This scenario is particularly relevant for hospital tenders and large specialty-distribution contracts.
Scenario 3: Product-specific manufacturing challenge
A competitor designs around a formulation or process patent and obtains its own approval. Kedrion’s response would depend on the scope of the patent claims, trade-secret protections and the competitor’s ability to establish equivalent quality and supply.
A conventional 180-day generic launch following a Paragraph IV certification is less relevant to most Kedrion plasma-derived products than a separately approved biologic competitor.
What is Kedrion’s geographic coverage?
Kedrion has an international operating model centered on Italy, Europe and the United States, with products distributed in additional markets through local regulatory and commercial partners.
Geographic strength depends on:
- Local biologics licenses
- Plasma import and export rules
- Government procurement
- Pharmacovigilance infrastructure
- Distribution partners
- Local manufacturing requirements
- Reimbursement and hospital purchasing systems
The United States remains strategically important because of its scale, high IVIG demand and relatively developed specialty-product distribution. Europe provides regulatory reach and proximity to Kedrion’s historical manufacturing base. Emerging markets offer volume opportunities but carry pricing, registration and supply-chain risks.
What revenue exposure does Kedrion have?
Kedrion is privately held, so it does not provide the same level of segment revenue disclosure as public competitors such as CSL, Grifols or Takeda. Product-level revenue, gross margin and U.S. market share are therefore not consistently available from public filings.
Revenue exposure is concentrated in:
- IVIG and immune globulin
- Hyperimmune globulins such as rabies immune globulin
- Albumin
- Government and hospital procurement
- U.S. and European specialty distribution
IVIG is strategically important because demand has grown with expanded diagnosis, chronic immune disorders and clinical use. The category is also exposed to plasma shortages, raw-material costs, manufacturing disruptions and competitive contracting.
Kedrion’s acquisition of BPL increases potential revenue scale but also raises integration costs and operational complexity. The transaction’s value depends on whether the combined company can improve utilization, maintain quality performance and avoid supply interruptions.
What are Kedrion’s principal strengths and weaknesses?
Strengths
- Integrated expertise in plasma-derived medicines
- Established products with regulatory histories
- Specialized hyperimmune portfolio
- Expanded scale after the BPL transaction
- Manufacturing and fractionation know-how
- Exposure to structurally important IVIG demand
- Ability to compete in government and hospital channels
Weaknesses
- Smaller plasma network than CSL Behring and Grifols
- Limited public financial transparency
- Dependence on donor plasma availability
- Product concentration in mature plasma categories
- Exposure to manufacturing and quality-system risk
- Lower ability than diversified pharmaceutical companies to absorb supply shocks
- Potential integration pressure from combining Kedrion and BPL assets
Key Takeaways
- Kedrion is a significant mid-sized plasma-derived therapeutics company, not a conventional patent-led pharmaceutical company.
- Its competitive position strengthened through the BPL acquisition and expanded manufacturing scale.
- The main competitors are CSL Behring, Grifols, Takeda, Octapharma, Biotest and ADMA Biologics.
- Orange Book and Paragraph IV analysis is less relevant than biologics licensing, Purple Book status and manufacturing competition.
- Kedrion’s strongest protections are plasma supply, manufacturing know-how, regulatory approvals and quality systems.
- Formulation and process patents can provide product-specific protection, but they are unlikely to create a broad company-wide exclusivity barrier.
- Biosimilar risk is limited by the complexity and heterogeneity of polyclonal plasma-derived products, although separately approved competitors remain a material threat.
- Revenue exposure is concentrated in IVIG, hyperimmune globulins, albumin and institutional procurement.
- The main commercial risks are plasma availability, manufacturing compliance, pricing pressure and integration execution.
FAQs
Does Kedrion manufacture biosimilars?
Kedrion’s core business is plasma-derived biologics, including immune globulin, hyperimmune globulin and albumin. These products are distinct from the monoclonal-antibody biosimilars that dominate current biosimilar competition.
Is Kedrion’s KEDRAB protected by a patent?
KEDRAB may be protected by product-specific formulation, manufacturing, regulatory and contractual rights. The commercial strength of those rights must be assessed against the applicable U.S. patent and biologics-license records rather than assumed from the brand name.
Can hospitals automatically substitute a competing IVIG for a Kedrion product?
Automatic substitution depends on the product, jurisdiction, purchasing rules and applicable regulatory status. IVIG products are not generally treated like interchangeable small-molecule generics.
Who owns Kedrion Biopharma?
Kedrion has historically been controlled by the Marcucci family, with institutional investment associated with Italian and private-equity capital. Ownership interests and transaction structures should be assessed from current corporate disclosures and transaction documents.
Is Kedrion a takeover target?
Kedrion’s plasma assets, manufacturing capacity and specialized products could attract strategic or financial buyers. Valuation would depend on plasma access, regulatory compliance, BPL integration, product profitability and the company’s capital structure.
References
- U.S. Food and Drug Administration. (n.d.). BIVIGAM prescribing information. https://www.accessdata.fda.gov
- U.S. Food and Drug Administration. (n.d.). GAMMAKED prescribing information. https://www.accessdata.fda.gov
- U.S. Food and Drug Administration. (n.d.). GAMMAPLEX prescribing information. https://www.accessdata.fda.gov
- U.S. Food and Drug Administration. (n.d.). KEDRAB prescribing information. https://www.accessdata.fda.gov
- U.S. Food and Drug Administration. (n.d.). Purple Book: Database of licensed biological products. https://purplebooksearch.fda.gov
- U.S. Food and Drug Administration. (n.d.). Biologics Price Competition and Innovation Act of 2009. https://www.fda.gov
- U.S. Code. (2024). 42 U.S.C. § 262: Regulation of biological products. https://uscode.house.gov
- Permira. (2022). Permira funds complete acquisition of Bio Products Laboratory in partnership with Kedrion. https://www.permira.com
